- Pear deepens its Prescription Digital Therapeutics (PDTs) pipeline and expands its platform outside of brain-related conditions
- Companies to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal (GI) space
- Collaboration combines Pear’s expertise in PDTs with Ironwood’s GI franchise and clinical development expertise
Pear Therapeutics, Inc. announced today that it has entered into an agreement with Ironwood Pharmaceuticals, Inc. to evaluate Prescription Digital Therapeutics (PDTs) for the treatment of selected indications within the gastrointestinal (GI) space.
This collaboration will leverage Pear’s platform and capabilities in PDTs with Ironwood’s innovative GI franchise expertise.
“We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of PDTs in treating GI diseases,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. “This represents an important step for Pear and broadens our pipeline to diseases outside the central nervous system and into a range of chronic conditions.”
“This agreement represents an attractive opportunity to develop first-in-class products that could help patients with GI diseases reach better outcomes,” said Tom McCourt, President of Ironwood. “At Ironwood, we are committed to helping patients with GI diseases, and are excited about exploring the potential of this innovative new treatment modality.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Business Wire
